Misplaced Pages

Levofloxacin: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 18:05, 26 September 2006 edit210.245.5.2 (talk) Gram-positive bacteria← Previous edit Revision as of 18:05, 26 September 2006 edit undo210.245.5.2 (talk) As approved by the US FDANext edit →
Line 27: Line 27:





== As approved by the US FDA ==


== Gram-positive bacteria == == Gram-positive bacteria ==

Revision as of 18:05, 26 September 2006

Pharmaceutical compound
Levofloxacin
Clinical data
Pregnancy
category
Routes of
administration
Oral, IV, Ophthalmic
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability99%
Protein binding24 to 38%
MetabolismRenal
Elimination half-life6 to 8 hours
ExcretionUrinary
Identifiers
IUPAC name
  • (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-
    (4-methyl-1-piperazinyl)-7-oxo-7H-pyrido
    -1,4-benzoxazine-6-carboxylic acid
CAS Number
PubChem CID
DrugBank
CompTox Dashboard (EPA)
ECHA InfoCard100.115.581 Edit this at Wikidata
Chemical and physical data
FormulaC18H20FN3O4
Molar mass361.368 g/mol g·mol

Levofloxacin is an advanced generation fluoroquinolone antibiotic, marketed by Ortho-McNeil under the trade name Levaquin in the US. In Europe, it is marketed by Sanofi-Aventis under the trade name of "Tavanic", and in Asia it is marketed by Daiichi under the trade name of Cravit. Levofloxacin has been launched in the Japanese market since 1993, and thus have had more than 12 years of experience in efficacy and safety globally. Chemically, levofloxacin is the S-enantiomer (L-isomer) of ofloxacin, and has approximately twice the potency of ofloxacin.

Levofloxacin is effective against a number of gram-positive and gram-negative bacteria. Because of its broad spectrum of action, levofloxacin is frequently prescribed empirically for a wide range of infections (e.g. pneumonia, urinary tract infection) before the specific causal organism is known. If the causal organism is identified, levofloxacin may be discontinued and the patient may be switched to an antibiotic with a narrower spectrum of activity. Levofloxacin is currently the only respiratory fluoroquinolone approved by the US FDA for the treatment of nosocomial pneumonia.



Gram-positive bacteria

Gram-negative bacteria

Other

Some information extracted from Levaquin Prescribing information.

Antibacterials that inhibit nucleic acid (J01E, J01M)
Antifolates
(inhibit bacterial
purine metabolism,
thereby inhibiting
DNA and RNA
synthesis)
DHFR inhibitor
Sulfonamides
(DHPS inhibitor)
Short-acting
Intermediate-acting
Long-acting
Other/ungrouped
Combinations
Other DHPS inhibitors
Quinolones
(inhibit bacterial
topoisomerase
and/or DNA gyrase,
thereby inhibiting
DNA replication)
1st generation
Fluoroquinolones
2nd generation
3rd generation
4th generation
Veterinary
Newer non-fluorinated
Related (DG)
Anaerobic DNA
inhibitors
Nitroimidazole derivatives
RNA synthesis
Rifamycins/
RNA polymerase
Lipiarmycins
  1. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
Categories: